Current Trends in Respiratory Diseases: Updates for the Primary Care Physician

Release Date: November 17, 2020
Expiration Date: November 17, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts to discuss current trends in diagnosing and treating important pulmonary diseases. Chronic obstructive pulmonary disease (COPD), asthma, pulmonary arterial hypertension (PAH), and rarer lung disorders—including interstitial lung disease (ILD) and idiopathic pulmonary fibrosis—have significant associated morbidity and mortality. Because of this, research into new therapies for these diseases is expanding, and novel treatments are being introduced to relieve the burden of these conditions among millions of patients.

As the role of primary care clinicians in a variety of disease states continues to evolve and expand, it is vital that they stay up-to-date on education surrounding current trends in the area. This half-day virtual summit with expert faculty is the ideal platform to close knowledge gaps in a variety of respiratory diseases for the primary care clinician. The activity will provide information on risk factors in pulmonary diseases, diagnostic criteria for rare respiratory diseases, and available and emerging treatment options to manage those diseases.

This educational activity is an archive of a live virtual symposium held on October 31, 2020.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Target Audience

This educational program is directed toward primary care physicians, nurses, nurse practitioners, and physician assistants.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess risk factors for pulmonary diseases and describe the diagnostic process
• Improve ability to correctly diagnose and differentiate rare respiratory diseases earlier during the course of disease to allow prompt intervention
• Compare different treatments available for pulmonary disorders
• Evaluate clinical trial data regarding emerging treatments for various pulmonary disorders and the potential use of these agents in clinical practice

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Steven D. Nathan, MD, FCCP
Professor of Medicine
Virginia Commonwealth University
Medical Director, Advanced Lung Disease and Lung Transplant Programs
Inova Fairfax Hospital
Falls Church, VA

Disclosures: Grant Research Support: Bellerophon Therapeutics, Gilead Sciences, Regeneron Pharmaceuticals, Roche, United Therapeutics; Consultant: Bellerophon Therapeutics, Boehringer- Ingelheim, Galapagos NV, Merck, Roche, Third Pole Therapeutics, United Therapeutics; Speakers Bureau: Bayer, Boehringer-Ingelheim, Roche, Veracyte .

Kristin Highland, MD, FCCP
Pulmonary Medicine
Cleveland Clinic
Cleveland, OH

Disclosures: Grant Research Support: Boehringer-Ingelheim, Gossamer Bio, Reata Pharmaceuticals, United Therapeutics, Viela Bio; Consultant: Boehringer- Ingelheim; Speakers Bureau: Actelion, Bayer, Boehringer-Ingelheim, United Therapeutics.

James P. Lamberti, MD
Pulmonary Medicine
Inova Fairfax Hospital
Falls Church, VA

Disclosures: Grant Research Support: Boehringer-Ingelheim, Genentech, Phillips; Consultant: Boehringer-Ingelheim, Janssen, Sanofi/Regeneron.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.